Medications not yet evaluated by P&T are considered NON-FORMULARY . . . . . Always check 2 unique patient identifiers - NAME and DATE OF BIRTH - at every step! . . . . . Please be sure to document all clinical activities daily.

<< Back to News

8/26/21 cb Baricitinib Criteria For Use - Adults and Peds
September 2, 2021

From: "Caitlin Bowman" <caitlin.bowman@hhsys.org>
To: "Pharmacists" <grp_allpharm@hhsys.org>
Sent: Thursday, August 26, 2021 12:30:31 PM
Subject: Baricitinib Criteria For Use - ADULTS and PEDS

Good afternoon Pharmacists,

 

In light of the IL-6 inhibitor (tocilizumab, sarilumab) shortage, another medication called baricitinib has become an option for the treatment of patients with COVID-19. Baricitinib is a janus kinase inhibitor that can be used under FDA Emergency Use Authorization for patients who meet the Huntsville Hospital Baricitinib Criteria For Use. The criteria is attached and can also be found on FormWeb under “COVID-19 Info for Pharmacists”. The infectious diseases physicians are aware of the IL-6 inhibitor shortage and may begin requesting baricitinib since it has recently been approved by The P&T Committee.

 

Please contact AMT if you have any questions regarding this criteria for use.






This site is intended for the staff of Huntsville Hospital.
While others may view accessible pages, Huntsville Hospital makes no warranty, express or implied,
as to the use of this information outside of Huntsville Hospital.
Please note than many documents are accessible via the provided link
only when connected to the Huntsville Hospital intranet.

Copyright © 2024 Rpharmy, LLC ­ All Rights Reserved